ESR1 and neoplasm: It has also demonstrated antitumor activity in ER-positive patient-derived xenograft (PDX) tumor models with ESR1 mutations and with models for cyclin-dependent kinase 4/6 (CDK4/6) inhibitor resistance [57,61].